Results 61 to 70 of about 110,241 (334)

Bloodstream yeast infections: a 15-month survey [PDF]

open access: yes, 2009
A 15-month survey of 412 bloodstream yeast isolates from 54 Belgian hospitals was undertaken. Candida albicans was the most common species (47.3%) followed by C. glabrata (25.7%), C. parapsilosis (8.0%), C. tropicalis (6.8%) and Saccharomyces cerevisiae (
Detandt, M   +3 more
core   +1 more source

A randomized, double-blind study of amorolfine 5% nail lacquer with oral fluconazole compared with oral fluconazole alone in the treatment of fingernail onychomycosis

open access: yesIndian Journal of Dermatology, 2019
Background: It is a challenge to treat onychomycosis due to frequent treatment failures and relapses. Systemic and topical therapies need to be combined to improve cure rates.
Somodyuti Chandra   +8 more
doaj   +1 more source

Fluconazole resistance in non-albicans Candida species in the United States, 2012-2021

open access: yesAntimicrobial Stewardship & Healthcare Epidemiology, 2023
Background: Candida spp can cause a variety of infections known as candidiasis, ranging from severe invasive infections to superficial mucosal infections of the mouth and vagina.
Emily Jenkins   +6 more
doaj   +1 more source

Molecular Evaluation of the mRNA Expression of the ERG11, ERG3, CgCDR1, and CgSNQ2 Genes Linked to Fluconazole Resistance in Candida glabrata in a Colombian Population

open access: yesJournal of Fungi
Introduction: The study of Candida glabrata genes associated with fluconazole resistance, from a molecular perspective, increases the understanding of the phenomenon with a view to its clinical applicability.
Leidy Yurany Cárdenas Parra   +3 more
doaj   +1 more source

Sphingolipid Inhibitors as an Alternative to Treat Candidiasis Caused by Fluconazole-Resistant Strains

open access: yesPathogens, 2021
Candida species are fungal pathogens known to cause a wide spectrum of diseases, and Candida albicans and Candida glabrata are the most common associated with invasive infections.
Rodrigo Rollin-Pinheiro   +6 more
doaj   +1 more source

Candida auris, what do paediatricians need to know? [PDF]

open access: yes, 2018
AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.Peer reviewedPublisher ...
Warris, Adilia
core   +1 more source

Tolerability of long-term fluconazole therapy

open access: yesJournal of Antimicrobial Chemotherapy, 2018
BACKGROUND Fluconazole is a commonly prescribed first-generation triazole antifungal. Although the toxicity profile of fluconazole has been evaluated in clinical trials, there are scant data regarding its tolerability with long-term therapy.
M. Davis   +3 more
semanticscholar   +1 more source

Comparative fitness trade-offs associated with azole resistance in Candida auris clinical isolates

open access: yesHeliyon
Multidrug-resistant yeast Candida auris is a serious threat to public health with documented survival in various hospital niches. The dynamics of this survival benefit and its trade off with drug resistance are still unknown for this pathogen.
Sourav Das   +7 more
doaj   +1 more source

Antifungal activities of tacrolimus in combination with antifungal agents against fluconazole-susceptible and fluconazole-resistant Trichosporon asahii isolates

open access: yesBrazilian Journal of Infectious Diseases, 2016
The antifungal activity of tacrolimus in combination with antifungal agents against different fungal species has been previously reported. Here we report the in vitro interactions between tacrolimus and amphotericin B, fluconazole, itraconazole, and ...
Thaís Felli Kubiça   +6 more
doaj   +1 more source

Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort. [PDF]

open access: yes, 2019
Fluconazole-induced alopecia is a significant problem for patients receiving long-term therapy. We evaluated the hair cycle changes of fluconazole in a rat model and investigated potential molecular mechanisms.
Aaron, Phylicia A   +15 more
core  

Home - About - Disclaimer - Privacy